The US FDA has published long-awaited guidelines on the non-proprietary naming of biological products, but biosimilar makers say adding a random four-letter suffix could needlessly complicate the prescribing system.
Army training is good for a biopharma career according to the US National Center for Therapeutics Manufacturing, which is seeking former military personnel interested in learning about bioprocessing.
Shire will use contractors to increase production of Cinryze, the half billion dollar-a-year Hereditary Angioedema (HAE) drug it bought with ViroPharma in 2014.
German biotech Immatics and the University of Texas have spent $60m on spin-out Immatics US to specialise in adoptive cellular therapies (ACT) for cancer.
API supplier Hepalink will buy Cytovance for $206m (€183m) in a deal the biologics CDMO says will help expedite its expansion plans.
A study commissioned and funded by reference biologic maker AbbVie has found biosimilars will have a smaller cost-saving impact on the US market than previously believed.